| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
An adenosine nucleoside inhibitor of dengue virus.
|
Proc Natl Acad Sci U S A
|
2009
|
2.20
|
|
2
|
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance.
|
J Pharm Sci
|
2011
|
1.14
|
|
3
|
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution.
|
J Pharm Sci
|
2011
|
1.04
|
|
4
|
Development of clinical dosage forms for a poorly water soluble drug I: Application of polyethylene glycol-polysorbate 80 solid dispersion carrier system.
|
J Pharm Sci
|
2004
|
1.04
|
|
5
|
PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
|
J Pharm Sci
|
2011
|
1.03
|
|
6
|
Inhibition of dengue virus RNA synthesis by an adenosine nucleoside.
|
Antimicrob Agents Chemother
|
2010
|
0.96
|
|
7
|
Case studies for practical food effect assessments across BCS/BDDCS class compounds using in silico, in vitro, and preclinical in vivo data.
|
AAPS J
|
2012
|
0.94
|
|
8
|
IV-IVC considerations in the development of immediate-release oral dosage form.
|
J Pharm Sci
|
2005
|
0.86
|
|
9
|
The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.
|
J Med Chem
|
2010
|
0.85
|
|
10
|
Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions.
|
Cancer Chemother Pharmacol
|
2012
|
0.83
|
|
11
|
A simplified PBPK modeling approach for prediction of pharmacokinetics of four primarily renally excreted and CYP3A metabolized compounds during pregnancy.
|
AAPS J
|
2013
|
0.83
|
|
12
|
Determination of N-methyl-4-isoleucine-cyclosporin (NIM811) in human whole blood by high performance liquid chromatography-tandem mass spectrometry.
|
Biomed Chromatogr
|
2007
|
0.82
|
|
13
|
Practical anticipation of human efficacious doses and pharmacokinetics using in vitro and preclinical in vivo data.
|
AAPS J
|
2009
|
0.81
|
|
14
|
Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability.
|
Biopharm Drug Dispos
|
2012
|
0.79
|
|
15
|
Utility of physiologically based modeling and preclinical in vitro/in vivo data to mitigate positive food effect in a BCS class 2 compound.
|
AAPS PharmSciTech
|
2013
|
0.79
|
|
16
|
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach.
|
J Pharm Sci
|
2011
|
0.79
|
|
17
|
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasets.
|
J Pharm Sci
|
2011
|
0.78
|
|
18
|
Application of physiologically based absorption modeling to formulation development of a low solubility, low permeability weak base: mechanistic investigation of food effect.
|
AAPS PharmSciTech
|
2014
|
0.76
|